

# Index

- Alternative assets, 14
- American Capital, 259, 263–264, 275–276
- Australia, 400, 405, 406, 407, 409
- Australasian private equity market, 395
- Benchmarking performance, 287–288, 290–297
  - advanced private equity benchmarking, 293–297
    - based on deal-level benchmarks, 293–294
    - alternative techniques, 292
    - public market benchmarks, using and interpreting, 291–292
    - traditional benchmarking approach, shortcomings of, 290–291
- Blackstone Group, 41, 43–44
- British Venture Capital Association (BVCA), 339, 381–382, 467–468
- Buyouts, international syndication of, 408–410
- CalPERS, 272, 274, 276, 336, 342–343
- Canada, private placements by small public entities in, 129–153
  - Canadian stock market, 130
  - discounts, 146–149
    - and long-run performance, 148–149
    - measure and stylized facts, 147–148
    - previous evidence and explanations, 146–147
  - regulation of, 131–132
    - regulatory response, 388
  - issuers, 132–140
    - financing strategies and clustering of issuers, 136–137
    - industry clustering, 135–136
    - operating performance, 137–138
    - postplacement performance, 139–140
    - preissue performance, 138–139
  - returns surrounding, 140–146
    - abnormal returns, estimation of, 140–141
    - differences in long-run performance, analysis of, 145
    - postissue return of public investors, 144–145
    - preissue return of public investors, 141–143
- Canada, venture capital and private equity in, 579–602
  - multivariate regression evidence, 588–598
    - capital-raising hurdles, 588–594
    - time to failure, 594–596
    - value-added, extent of, 596–598
  - 2008 YORKbiotech survey data, description of, 582–588
- Capital Asset Pricing Model (CAPM), 20–21
- “Cash drag,” 58
- Claw-backs, 372
- Cobb-Douglas production functions, 303
- Companies Act
  - 1928/1929, 498
  - 1948, 499
  - 1961, 499
  - 1985, 499
  - 2006, 500
- CompuDyne Corporation, 123–124
- Contractual arrangements, 368–379
  - limited partnership structure, 369–373
  - relationship between the fund and its portfolio companies, 376–379
  - restrictive covenants, 373–376
- Convertible stock, 377
- Denmark, private equity in, 555–578
  - history of buyouts, 556–558
  - portfolio companies, consequences for capital structure of, 558–565
    - case studies, 563–564
    - empirical investigation, 560–563
    - investments, financial performance of, 564
    - leverage and takeovers, 558
    - private equity funds, capital structure of, 559–560
  - tax payments, implications for, 565–575
    - complications, 573–575
    - hypothetical case, 572–573
    - implications for corporate tax payments, 567–571
    - private equity takeover, example of, 566–567
    - private equity takeovers, wider tax implications of, 571–572
    - taxes and takeovers, 565–566

- Deutsche Borse (German stock exchange), 160, 163, 512, 517
- Disclosure and fund reporting, enhancing, 386–387
- Econometric analysis and modeling, 213–218
- Efficient markets hypothesis, 302
- Emerging markets, private equity in, 410–411, 419–436
  - determinants of, 421–424
  - importance of allocation criteria, survey among institutional investors on, 424–432
  - investors' preferences regarding different emerging regions, 431–432
  - perceptions of particular allocation criteria, 429–431
  - international comparison, 420–421
- Employment Retirement Income Stabilization Act (1979), 438
- Employment, wage, and productivity effects of transactions, 311–332
  - employment and productivity identities, 313–315
  - empirical studies
    - U.K., 323–327
    - U.S., 315–323
- Endowments, 10, 11, 12
- Europe, private equity in, 437–461
  - history, 438–439
  - internationalization of private equity, 446–450
  - investment, 441–446
    - divestment at cost, 446
    - evolution activity flows, 442
    - fund-raising, 444
    - industrial sectors, 445
    - investment benchmarks database, 442
    - stage distribution of investments, 443
  - performance, 450–456
    - evidence, 453–456
    - literature, 450–451
    - measures, 451–453
    - structure of, 439–441
- European Venture Capital Association (EVCA), 339, 384–385, 441, 453, 457, 467–468
- Fama-French model, 21–23
- Financial Service Authority (U.K.), 385–386
- Fortress Investment Group, 40, 43–44
- Foundations, 10, 11, 12
- France, 400, 402, 403, 404, 407, 408, 409
- Franklin Mutual Advisers, 168
- Fund-of-funds, 10, 11, 12, 14, 16, 397
- Fund-raising
  - international, brief overview of, 396–398
  - methods
    - nontraditional, 38–39
    - traditional, 36–38
- patterns, 34
  - of buyout funds, 35
  - of European private equity firms, 36
- Generalized Method of Moments (GMM), 267, 269
- Generally accepted accounting principles (GAAP), 338
- Geometric returns, 266–267
- German stock exchange (Deutsche Borse), 160, 163, 512, 517
- Germany, 388–389, 400, 401, 402, 403, 404, 405, 407, 408, 409
  - investments
    - according to financing stages in, 1990–2007, 526, 527
    - by industry, 1990–2007, 522
    - by states, 1990–2007, 524
  - private equity market, 401
  - regulatory responses to hedge fund and private equity in, 388–389
  - venture capital and private equity in, 511–553
    - German venture capital industry, development of, 513–534
    - going public as exit route for venture capital and performance of venture-backed IPOs, 534–548
- Governance and investor protection, 387
- Hedge funds' activism, 155–193
  - approach to activism, 159–162
  - incumbent management, how hedge funds engage a fight against, 163–167
    - stake owned, wolf packs, empty voting, and hidden ownership, 165–167
  - market data and trends toward convergence, 156–159
  - private equity and hedge funds, 157–159
  - targeted companies, features of, 162–163
- Hurdle rate, 440
- Icahn, Carl, 156, 160, 161, 163
  - versus Time Warner, Inc., clinical study of, 167–182
    - activist intervention, 172–174
    - event study analysis, 177–182
    - parties involved, 168–172
    - path followed, 174
- Institutional investment in private equity, 9–29
  - corporate, 13
  - government entities, 13
  - motivation for
    - key features of, 11
    - nonfinancial, 13
- Internal rate of return (IRR), 17–19, 197–199, 201–221, 234, 242–245, 271, 364, 452, 453–455

- International private equity flows, 395–417
  - fund-raising, brief overview of, 396–398
  - investments of private equity funds in western Europe, North America, and Australia, 398–410
  - international syndication of buyouts, 408–410
  - investor countries, most important, 399–402
  - median and average values of nondomestic investments, annual trend of, 403
  - regional clustering of investment market, 406–408
  - target countries, most important, 402–406
  - private equity in emerging markets, 410–411
- International Private Equity and Venture Capital Valuation Guidelines, 340–341
- IPOs, 31–51, 238–239, 458
  - fund-raising methods
    - nontraditional, 38–39
    - traditional, 36–38
  - private equity
    - industry, recent trends in, 33–36
    - performance and implications for the future, 39–44
  - sovereign wealth funds complementing and substituting for, 45–48
- Italy, 400, 402, 403, 404, 405
  - private equity and leveraged buyouts in, 463–510
    - buyout market, 465–468
    - LBO scheme and related criticisms, 468
    - legal environment, 469–480
    - past debate on legitimacy of, 496–502
    - 2004 reform, impact of, 480–494
- Jana Partners, 168
- Jenkins Committee (1962), 495
- Jensen hypothesis, 315
- King Pharmaceuticals, 160–161
- Langley Partners, 124–125
- Leveraged buyout (LBO) funds, 31–32
- Leveraged buyouts (LBOs), 303–308, 311–312, 365, 463–510
  - impact on productivity, 303–308, 311–312
  - private equity and, in Italy, 463–510
    - buyout market, 465–468
    - LBO scheme and related criticisms, 468
    - legal environment, 469–480
    - past debate on legitimacy of, 496–502
    - 2004 reform, impact of, 480–494
- Limited partnership structure, 369–373
  - negotiating the terms, 371
- Liquidation preference, 377
- Luxembourg, 400, 401, 402, 403, 408
- Management buyouts (MBOs), impact on productivity, 303–308, 365
- Managers, private equity fund, 59–60, 284–286
  - deal flow, 286
  - experience, 286
  - focal and prior funds, difference between, 286
  - listed, 59–60
  - performance track record, 286
- Market access, enhancing, 387
- Maximum Likelihood, 266, 267, 268
- Mezzanine capital, 56, 204
- Middle-market buyouts, 229–255
  - background, context, and prior literature, 230–241
  - descriptive statistics, 234–236
  - sample and data, 232–233
  - variables, 233–234
  - regression results, 241–245
- Monte Carlo simulation—199, 197, 218–221
- Mylan Laboratories, 160–161
- National Venture Capital Association (NVCA), 339
  - comparison to II-EV guidelines, 341
- Netherlands, regulatory responses to hedge fund and private equity in, 389
- New Zealand, 402, 403, 405
- North America, regional clustering of international PE investment market in, 407
- Onex, 261–263/275
- Pension funds, 10, 11, 12
- Peracs Private Equity Selection Efficiency Measure™ (PESEM), 289, 294
- PIPE market, 111–128
  - contract terms in, 115–118
    - antidilution protection, 115
    - company-forced conversion, 117
    - investor board representation, 116
    - investor call option, investor right of first refusal, and company put option, 117–118
  - investor registration rights, 116
  - redemption rights, 116
  - trading/hedging restrictions, 116–117
- definition, 112–115
- distribution of, by industries, 115
- firms issuing PIPEs, 118–120
  - cost of PIPEs, 119
  - stock performance at closing and in the long run, 119–120
- future of, 126–127
- investors in, 120–122
- issues in, and SEC regulations, 123–126
- placement agents, role of, 122
- security structure of, 113

- Preemptive right, 378
- Private equity
  - in Canada, 579–602
    - multivariate regression evidence, 588–598
    - 2008 YORKbiotech survey data, description of, 582–588
  - in Denmark, 555–578
    - history of buyouts, 556–558
    - portfolio companies, consequences for capital structure of, 558–565
    - tax payments, implications for, 565–575
  - in emerging markets, 410–411, 419–436
    - determinants of, 421–424
    - importance of allocation criteria, survey among institutional investors on, 424–432
    - international comparison, 420–421
  - employment, wage, and productivity effects of transactions, 311–332
    - employment and productivity identities, 313–315
    - empirical studies (U.S./U.K.), 315–327
  - in Europe, 437–461
    - history, 438–439
    - internationalization of private equity, 446–450
    - investment, 441–446
    - performance, 450–456
    - structure of, 439–441
  - financing styles, 56
  - venture capital and, in Germany, 511–553
    - German venture capital industry, development of, 513–534
    - going public as exit route for venture capital and performance of venture-backed IPOs, 534–548
  - industry, recent trends in, 23–36
  - institutional investment in, 9–29
    - motivations and behavior, 9–13
    - performance, 16–25
    - structure and strategies, 13–16
  - international, 395–417
    - fund-raising, brief overview of, 396–398
    - investments of private equity funds in western Europe, North America, and Australia, 398–410
    - private equity in emerging markets, 410–411
  - introduction to, 1–6
  - investment styles, 55–56
  - investors, types of, 10
  - in Italy, 463–510
    - buyout market, 465–468
    - LBO scheme and related criticisms, 468
    - legal environment, 469–480
    - past debate on legitimacy of, 496–502
    - 2004 reform, impact of, 480–494
  - listed, 53–70
    - definitions and categorization, 54–60
    - direct, 59
    - empirical insights on, 60–68
    - indirect, 58
    - organizational structures of, 57
  - real effects of, 301–310
    - evidence of, 301–307
    - research agenda, 307–308
    - studies of, 304–305
  - regulation, comparative analysis of, 359–394
    - contractual arrangements, 368–379
    - coregulation, 382–384
    - growth of private equity, 363
    - legal tools, 3886–388
    - performance of private equity, 364–365
    - regulatory response, 384–386, 388–389
    - self-regulation, 379–382
  - returns to, measuring, 17–19, 23–25
    - capital flows, 24
    - fund size, 23–24
    - legality, 24–25
    - manager experience, 24
  - risk, measurement of, 20–25
    - multifactor models, 21–23
    - single-factor models, 20–21
  - risk and return of, 257–282
    - fund data, 260, 269–270, 272–274
    - investment data, 259–260, 261–264, 269–270, 271–272
    - publicly traded vehicles, 258, 266, 270
    - round valuation data, 258–259, 266–269, 270–271
    - sample biases, 260, 265–266
    - staleness correction, 279–280
  - stylized model of investment structures, 14
  - supply-and-demand side of, 365–368
  - syndication of, 73–92
    - future of syndication research, 85–89
    - motives for, 75–78
    - partner selection, 78–81
      - and performance, 85–86
      - structuring and managing, 81–84
  - unlisted, 56–58
    - organizational structures of, 57
- Private equity firms, geographical concentration of top 50, 35
- Private equity funds, 14
  - CalPERS report, 274
  - managers, 59–60, 284–286
    - deal flow, 286
    - experience, 286
    - focal and prior funds, difference between, 286
  - listed, 59–60
  - performance track record, 286

- performance, projection of, 197–228
  - related literature, 199–201
  - and risk management, simulation approach for, 201–221
  - simulation results for two fictitious venture capital funds, 221–224
  - potential reporting biases of, 345–346
- publicly traded, 259
- reporting biases of valuation, 348–352
- selection, 283–299
  - advanced benchmarking, 290–297
  - future performance, factors correlated with, 286–287
  - hypothesis development, 284–285
  - measurement and operationalization, 285–286
  - measuring efficiency, approach to, 287–288
  - Peracs Private Equity Selection Efficiency Measure™ (PESEM), 289
  - performance-based selection rules, efficiency of, 289–290
  - public market benchmarks, using and interpreting, 291–292
  - research approach, 285
  - traditional benchmarking approach, shortcomings of, 290–291
- structure of venture capital and, 93–109
  - empirical tests, 99–105
  - optimal effort levels, 94–98
  - optimal portfolio size and profit-sharing rule, 98–99
- Private Equity Monitor (PEM®), 482–486
- Private placements by small public entities (Canada), 129–153
  - Canadian stock market, 130
  - discounts, 146–149
    - and long-run performance, 148–149
    - measure and stylized facts, 147–148
    - previous evidence and explanations, 146–147
  - regulation of, in Canada, 131–132
  - issuers, 132–140
    - financing strategies and clustering of issuers, 136–137
    - industry clustering, 135–136
    - operating performance, 137–138
    - postplacement performance, 139–140
    - preissue performance, 138–139
  - returns surrounding, 140–146
    - abnormal returns, estimation of, 140–141
    - differences in long-run performance, analysis of, 145
    - postissue return of public investors, 144–145
    - preissue return of public investors, 141–143
- Prudent Man Rule, 31
- Public Market Equivalent (PME), 67–68
- Regression analysis, 103–105
- Regulation D, 112–113, 120, 127
- Regulatory response, 384–386, 388–389
  - Canada, 388
  - Germany, 388–389
  - Netherlands, 389
  - United Kingdom, 389
- Risk, measurement of, 20–25, 267–268
  - abnormal performance and, 267–268
  - multifactor models, 21–23
    - beta estimates, 22
  - single-factor models, 20–21
    - beta estimates, 21
- Risk reduction, 76–77
  - improved deal selection, 76–77
  - value added, 77
- Risk sharing, 75–76
- SAC Capital Advisors, 168
- Scandinavia, regional clustering of international PE investment market in, 406–407
- Schedule 13D, 163–165
- Seasoned equity offerings (SEOs), 111
- SEC vs. *Rhino Advisers*, 125
- Seltona Corporation, 125
- Shane, Hilary L., 123–124
- Small business investment companies (SBICs), 365
- Sovereign wealth funds, 16, 33
  - complementing and substituting for private equity investments, 45–48
    - major, 46
- Spain, 400, 402, 403, 404, 405
- Stabilization funds. *See* Sovereign wealth funds
- Staleness correction, 279–280
- Subprime mortgage crisis, 37–38
- Sweden, 400, 402, 403, 404, 405, 409
- Swensen, David, 279
- Switzerland, 400–401
- Syndication of private equity, 73–92
  - future of syndication research, 85–89
    - club deals, 87
    - cross-border syndicates, 87–89
    - financial distress, 87
    - interaction between debt and equity, 87
    - secondary buyouts, 89
  - motives for, 75–78
    - access to deal flow, 77–78
    - risk reduction, 76–77
    - risk sharing, 75–76
  - partner selection, 78–81
  - and performance, 85–86

- Syndication of private equity (*Continued*)  
structuring and managing, 81–84  
contractual enforcement, 82–83  
decision making, 84  
equity ownership structure, 81  
investees, monitoring of, 83  
investment agreement, 81–82
- Three-Factor Pricing Model (TFPM), 140. *See also*  
Fama-French model
- 3i Group, 41–44, 259
- Time Warner, Inc., 156, 160, 161, 163  
Carl Icahn, versus, clinical study of, 167–182
- Total value to paid-in (TVPI), 364, 452
- United Kingdom, 400, 401, 402, 403, 404, 405, 406,  
409. *See also* Europe, private equity in  
regulatory responses to hedge fund and  
private equity in, 389
- Valuation and financial disclosure in the private  
equity industry, 335–357  
disclosure and reporting patterns of  
venture-backed portfolio firms, 347–352  
reporting biases of private equity funds  
valuation, 348–352  
institutional setup, 337–342  
guidelines for private equity funds, 339–342  
main problems and conflicts of interest,  
342–343  
rules for privately held (portfolio) firms,  
337–339
- voluntary versus mandatory disclosure,  
incentives for, 343–347  
financial standards, disclosure, and  
regulation, 346–347  
firm-specific information, disclosure of,  
344–345  
potential reporting biases of private equity  
funds, determinants of, 345–346
- Venture capital (VC), 437  
in Canada, 579–602  
multivariate regression evidence, 588–598  
2008 YORKbiotech survey data, description  
of, 582–588  
funds, 31–33, 365–368  
corporate, 365  
in Germany, 511–553  
German venture capital industry,  
development of, 513–534  
going public as exit route for venture capital  
and performance of venture-backed  
IPOs, 534–548  
and private equity portfolios, structure of,  
93–109  
empirical tests, 99–105  
optimal effort levels, 94–98  
optimal portfolio size and profit-sharing  
rule, 98–99
- Venture capital trusts (VCTs), 440
- VentureXpert (Thomson Financial), 17–18, 265  
summary cash-flow data, 273
- Walker Guidelines, 381–382, 383
- Wendy's International, Inc., 165